SPEAKER: Amanda Falk Vargas
ROOM: Versailles 1/2
CONTACT HOURS: 1
CRNI RUs: 2

Anti-amyloid antibody infusions are being prescribed for mild Alzheimer’s disease. Considerations for these infusions include patient eligibility, patient and caregiver education, and adverse reactions. Updates to insurance drug coverage pathways and potential registry requirements will be reviewed. This session will use case studies to describe an effective and comprehensive referral and treatment process. 

Learning Objectives: At the conclusion of this session, learners will be able to: Describe the mechanism of action of anti-amyloid medications. Differentiate between eligible and ineligible patients for anti-amyloid antibody therapy. Develop an infusion therapy process to maximize the benefit of anti-amyloid antibody therapy for patients with Alzheimer’s disease